Development of Combination Treatment Targeting Triple-Negative Breast Cancer
Abstract
Treatment of triple-negative breast cancer (TNBC) is a challenge due to its aggressive behavior, poor clinical outcome, and prone to relapse. TNBC accounts for ~15% of the breast cancer cases with higher histological grades and poorly differentiated cell type exhibiting aggressive characteristics and poor prognosis. The heterogeneity and lack of actionable targets has been a major challenge in developing better therapies for TNBC. Taxane chemotherapy remains the standard-of-care treatment option for advance-stage TNBC patients; however, the response to these treatment(s) is often short and associated with non-responsiveness and poor prognosis with median overall survival of 9-12 months. Therefore, new target-based approach is urgently needed for the effective management of this aggressive form of disease. Our proposal aims in the development of new combinatorial therapy for the treatment of TNBC by the use of existing Dopamine D1 Receptor (D1R) agonist and EZH2 inhibitors as a better efficacious treatment modality. We strongly feel this combinatorial treatment is translatable to the clinic and will provide better outcome to TNBC patients improving their quality of life.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Mar 10, 2021
- Source ID
- W81XWH2010065
Entities
People
- Eswar Shankar
Organizations
- Case Western Reserve University
- United States Army